SIM0237

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

145 competitors in Efficacy

#DrugCompanyPhaseTrials

1

Oncovin

Eli Lilly

Phase 3

42

Tivicay

GSK

Phase 3

23

Rogaine

Pfizer

Phase 3

14

Rayos

RRoxane Laboratories

Phase 3

55

Cytoxan

BBaxter Healthcare Corporation

Phase 3

36

Alimta

SShawn Eagle

Phase 3

37

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

28

Insulin 320

Novo Nordisk

Phase 3

59

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

110

QL2107

Qilu Pharmaceutical Co., Ltd.

Phase 3

1Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Efficacy1 trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Recruiting·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT06186414·152 enrolled

Advanced Solid Tumors1 trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

Terminated·Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT05781360·192 enrolled

Details

Drug Info

Related News